Patents by Inventor Jacques Simard

Jacques Simard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chromosome 17P-linked prostate cancer susceptibility gene
    Patent number: 6844189
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human prostate cancer predisposing gene (HPC2), some alleles of which cause susceptibility to cancer, in particular prostate cancer. More specifically, the present invention relates to germline mutations in the HPC2 gene and their use in the diagnosis of predisposition to prostate cancer. The invention also relates to presymptomatic therapy of individuals who carry deleterious alleles of the HPC2 gene. The invention further relates to somatic mutations in the HPC2 gene in human prostate cancer and their use in the diagnosis and prognosis of human prostate cancer. Additionally, the invention relates to somatic mutations in the HPC2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers.
    Type: Grant
    Filed: November 5, 1999
    Date of Patent: January 18, 2005
    Assignees: Myriad Genetics, Inc., University of Utah Research Foundation, Hospital for Sick Children
    Inventors: Sean V. Tavtigian, David H.-F. Teng, Jacques Simard, Johanna M. Rommens, Lisa A. Cannon Albright, Susan L. Neuhausen
  • Chromosome 17p-linked prostrate cancer susceptibility gene and a paralog and orthologous genes
    Publication number: 20030120052
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human prostate cancer predisposing gene (HPC2), some alleles of which cause susceptibility to cancer, in particular prostate cancer. More specifically, the present invention relates to germline mutations in the HPC2 gene and their use in the diagnosis of predisposition to prostate cancer. The invention also relates to presymptomatic therapy of individuals who carry deleterious alleles of the HPC2 gene. The invention further relates to somatic mutations in the HPC2 gene in human prostate cancer and their use in the diagnosis and prognosis of human prostate cancer. Additionally, the invention relates to somatic mutations in the HPC2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers.
    Type: Application
    Filed: November 20, 2001
    Publication date: June 26, 2003
    Applicant: Myriad Genetics, Inc.
    Inventors: Sean V. Tavtigian, David H. F. Teng, Jacques Simard, Johanna M. Rommens
  • Chromosome 17p-linked prostrate cancer susceptibility gene and a paralog and orthologous genes
    Publication number: 20030045704
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human prostate cancer predisposing gene (HPC2), some alleles of which cause susceptibility to cancer, in particular prostate cancer. More specifically, the present invention relates to germline mutations in the HPC2 gene and their use in the diagnosis of predisposition to prostate cancer. The invention also relates to presymptomatic therapy of individuals who carry deleterious alleles of the HPC2 gene. The invention further relates to somatic mutations in the HPC2 gene in human prostate cancer and their use in the diagnosis and prognosis of human prostate cancer. Additionally, the invention relates to somatic mutations in the HPC2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers.
    Type: Application
    Filed: November 20, 2001
    Publication date: March 6, 2003
    Applicant: Myriad Genetics, Inc.
    Inventors: Sean V. Tavtigian, David H.F. Teng, Jacques Simard, Johanna M. Rommens
  • Chromosome 17p-linked prostrate cancer susceptibility gene and a paralog and orthologous genes
    Publication number: 20030044959
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human prostate cancer predisposing gene (HPC2), some alleles of which cause susceptibility to cancer, in particular prostate cancer. More specifically, the present invention relates to germline mutations in the HPC2 gene and their use in the diagnosis of predisposition to prostate cancer. The invention also relates to presymptomatic therapy of individuals who carry deleterious alleles of the HPC2 gene. The invention farther relates to somatic mutations in the HPC2 gene in human prostate cancer and their use in the diagnosis and prognosis of human prostate cancer. Additionally, the invention relates to somatic mutations in the HPC2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers.
    Type: Application
    Filed: November 20, 2001
    Publication date: March 6, 2003
    Applicant: Myriad Genetics, Inc.
    Inventors: Sean V. Tavtigian, David H.F. Teng, Jacques Simard, Johanna M. Rommens
  • Prostate cancer susceptible CA7 CG04 gene
    Patent number: 6440699
    Abstract: A human gene which is here named CA7 CG04 has been identified in which mutations have been found which have been correlated with prostate cancer.
    Type: Grant
    Filed: May 11, 2000
    Date of Patent: August 27, 2002
    Assignees: Myriad Genetics, Inc., Hospital for Sick Children, The
    Inventors: Sean V. Tavtigian, Brad Swedlund, Jacques Simard, Johanna M. Rommens
  • Chromosome 17p-linked prostate cancer susceptibility gene and a paralog and orthologous genes
    Patent number: 6333403
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human prostate cancer predisposing gene (HPC2), some alleles of which cause susceptibility to cancer, in particular prostate cancer. More specifically, the present invention relates to germline mutations in the HPC2 gene and their use in the diagnosis of predisposition to prostate cancer. The invention also relates to presymptomatic therapy of individuals who carry deleterious alleles of the HPC2 gene. The invention further relates to somatic mutations in the HPC2 gene in human prostate cancer and their use in the diagnosis and prognosis of human prostate cancer. Additionally, the invention relates to somatic mutations in the HPC2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: December 25, 2001
    Assignees: Myriad Genetics, Inc., The Hospital for Sick Children
    Inventors: Sean V. Tavtigian, David H. F. Teng, Jacques Simard, Johanna M. Rommens
  • Chromosome 13-linked breast cancer susceptibility gene
    Patent number: 6124104
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast cancer predisposing gene (BRCA2), some mutant alleles of which cause susceptibility to cancer, in particular breast cancer. More specifically, the invention relates to germline mutations in the BRCA2 gene and their use in the diagnosis of predisposition to breast cancer. The present invention further relates to somatic mutations in the BRCA2 gene in human breast cancer and their use in the diagnosis and prognosis of human breast cancer. Additionally, the invention relates to somatic mutations in the BRCA2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA2 gene, including gene therapy, protein replacement therapy and protein mimetics.
    Type: Grant
    Filed: March 20, 1998
    Date of Patent: September 26, 2000
    Assignees: Myriad Genectics, Inc., Endo Recherche, Inc., HSC Reseach & Development Limited Partnership, Trustees of the University of Pennsylvania
    Inventors: Sean V. Tavtigian, Alexander Kamb, Jacques Simard, Fergus Couch, Johanna M. Rommens, Barbara L. Weber
  • Chromosome 13-linked breast cancer susceptibility gene
    Patent number: 6033857
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast cancer predisposing gene (BRCA2), some mutant alleles of which cause susceptibility to cancer, in particular breast cancer. More specifically, the invention relates to germline mutations in the BRCA2 gene and their use in the diagnosis of predisposition to breast cancer. The present invention further relates to somatic mutations in the BRCA2 gene in human breast cancer and their use in the diagnosis and prognosis of human breast cancer. Additionally, the invention relates to somatic mutations in the BRCA2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA2 gene, including gene therapy, protein replacement therapy and protein mimetics.
    Type: Grant
    Filed: March 20, 1998
    Date of Patent: March 7, 2000
    Assignees: Myriad Genetics, Inc., Endo Recherche, Inc., HSC Research & Development Limited Parntership, Trustees of the Univ. of Pennsylvania
    Inventors: Sean V. Tavtigian, Alexander Kamb, Jacques Simard, Fergus Couch, Johanna M. Rommens, Barbara L. Weber
  • Chromosome 13-linked breast cancer susceptibility gene
    Patent number: 5837492
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast cancer predisposing gene (BRCA2), some mutant alleles of which cause susceptibility to cancer, in particular breast cancer. More specifically, the invention relates to germline mutations in the BRCA2 gene and their use in the diagnosis of predisposition to breast cancer. The present invention further relates to somatic mutations in the BRCA2 gene in human breast cancer and their use in the diagnosis and prognosis of human breast cancer. Additionally, the invention relates to somatic mutations in the BRCA2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA2 gene, including gene therapy, protein replacement therapy and protein mimetics.
    Type: Grant
    Filed: April 29, 1996
    Date of Patent: November 17, 1998
    Assignees: Myriad Genetics, Inc., Endo Recherche, Inc., HSC Research & Development Limited Partnership, Trustees of the University of Pennsylvaina
    Inventors: Sean V. Tavtigian, Alexander Kamb, Jacques Simard, Fergus Couch, Johanna M. Rommens, Barbara L. Weber
  • Linked breast and ovarian cancer susceptibility gene
    Patent number: 5709999
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 20, 1998
    Assignees: Myriad Genetics Inc., Centre de Recherche du Chul, Cancer Institute
    Inventors: Donna M. Shattuck-Eidens, Jacques Simard, Francine Durocher, Mitsuuru Emi, Yusuke Nakamura
  • Linked breast and ovarian cancer susceptibility gene
    Patent number: 5693473
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 2, 1997
    Assignees: Myriad Genetics, Inc., Centre de Recherche du Chul, Cancer Institute
    Inventors: Donna M. Shattuck-Eidens, Jacques Simard, Francine Durocher, Mitsuuru Emi, Yusuke Nakamura